CellCare Therapeutics is a forward-thinking biopharmaceutical company at the forefront of developing next-generation cell therapies. Our mission is to harness the power of cellular biology to create transformative treatments for complex diseases, initially focusing on hard-to-treat cancers and debilitating regenerative conditions. We are committed to scientific excellence, innovation, and translating groundbreaking research into tangible benefits for patients worldwide. Our pipeline includes CAR-T and iPSC-derived therapeutic candidates progressing through various stages of clinical development.
Central hub for research and development, clinical operations, corporate administration, and strategic partnerships.
State-of-the-art laboratories for cell engineering, GMP-compliant process development suites, collaborative workspaces, and advanced bioanalytical capabilities.
A dynamic, collaborative, and science-driven environment that fosters innovation, encourages intellectual curiosity, and prioritizes patient impact. We value teamwork, integrity, and a relentless pursuit of solutions to complex medical challenges.
Strategically located in one of the world's leading biotech ecosystems, providing unparalleled access to top-tier talent, renowned research institutions, and potential collaborators, which accelerates our R&D efforts and innovation.
While headquartered in Cambridge, MA, CellCare Therapeutics maintains a growing global presence. We operate a significant research and clinical development office in South San Francisco, CA, and a European operational hub in Leiden, Netherlands. Our clinical trials are conducted across North America, Europe, and increasingly in other key international regions. We actively seek global partnerships to advance our therapeutic pipeline and prepare for potential worldwide commercialization of our innovative cell therapies.
100 Technology Square
Cambridge
MA
USA
Address: 200 Oyster Point Blvd, Suite 300
Supports engagement with West Coast academic partners, contract research organizations (CROs), and facilitates patient recruitment and site management for clinical trials in the western United States.
Address: Bio Science Park Leiden, Mendelweg 30
Manages clinical trial activities across multiple European countries, engages with European regulatory bodies like the EMA, and builds relationships with key opinion leaders and patient advocacy groups in the region.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Cell Care Therapeutics' leadership includes:
Cell Care Therapeutics has been backed by several prominent investors over the years, including:
CellCare Therapeutics has strategically strengthened its leadership team over the past year with key appointments in clinical development and operations, alongside a planned transition in a senior research role to bolster our advisory capabilities.
Discover the tools Cell Care Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
CellCare Therapeutics primarily utilizes a standard corporate email format for its employees. The most common structure is the first initial followed by the last name, or the full first name followed by the full last name, separated by a period. For example, 'jdoe@cellcaretherapeutics-example.com' or 'john.doe@cellcaretherapeutics-example.com'. Variations may exist for common names or specific internal conventions.
flast@cellcaretherapeutics-example.com (e.g., jdoe@cellcaretherapeutics-example.com) OR first.last@cellcaretherapeutics-example.com
Format
jdoe@cellcaretherapeutics-example.com
Example
85%
Success rate
BioPharma Today (Example News) • May 15, 2024
CellCare Therapeutics today shared encouraging interim results from its ongoing 'CELLERATE-01' Phase 2 clinical trial evaluating CCT-101, its lead autologous CAR-T candidate, in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The data, presented at an oncology conference, demonstrated a promising overall response rate (ORR) and a manageable safety profile, consistent with previous findings....more
Global Biotech Wire (Example News) • March 5, 2024
CellCare Therapeutics announced a multi-year research collaboration with the Stanford University School of Medicine's Institute for Stem Cell Biology and Regenerative Medicine. The partnership will focus on leveraging CellCare's proprietary induced pluripotent stem cell (iPSC) differentiation technology and Stanford's expertise in neurological disease modeling to develop novel cell-based therapies for conditions like Parkinson's disease....more
Company Press Release • January 20, 2024
CellCare Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to CCT-205, an investigational allogeneic cell therapy candidate, for the treatment of pancreatic cancer. This designation provides incentives to support the development of drugs for rare diseases....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Cell Care Therapeutics, are just a search away.